Announcements Trials
Browse Landscape

Status

Completed 6Terminated 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Neoplasm, Residual 1Multiple Myeloma 1

Interventions

Dexamethasone 97daratumumab 57Lenalidomide 53Bortezomib 38Cyclophosphamide 37pomalidomide 36Calcium Dobesilate 25carfilzomib 24fludarabine 22talquetamab 19isatuximab 17iberdomide 17Specimen Handling 16Magnetic Resonance Spectroscopy 16Biopsy 14selinexor 13dexamethasone acetate 12belantamab mafodotin 12Melphalan 12dexamethasone 21-phosphate 11auricularum 10venetoclax 8fludarabine phosphate 7elotuzumab 7X-Rays 6tocilizumab 5Blood Specimen Collection 5ruxolitinib 4ixazomib 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Transplantation, Autologous × Plasma cell × Clear all
NCT06463717 2024-06-24

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

First Affiliated Hospital of Zhejiang University

Recruiting
210 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡